In this study, researchers test the anti-tumor effects of combined IL-24/OSM adenoviral-mediated tumor suppressor gene co-transfer in A375 cells. Interleukin-24 (IL-24) is a cytokine-tumor suppressor that exhibits anti-tumor properties. Oncostatin M (OSM) inhibits the proliferation of various solid tumor cell lines. Researchers combined IL-24 and OSM to form a bicistronic adenovirus and tested its effect on A375 cells in vivo and in vitro. Results indicate that IL-24/OSM reduces certain protein expressions in A375 cell cycles and this activity is closely associated with the activation of an apoptotic pathway and inhibition of tumor angiogenesis. Therefore, combining two or more tumor suppressors may lead to a new strategy of treating melanoma. [LINK]
An A375 Transfection Reagent is commercially available from Altogen Biosystems, which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found here.
An A375 Transfection Reagent is commercially available from Altogen Biosystems, which includes standard and reverse protocols to transfect A375 cells. A xenograft model of this cell line can be found here.
Comments
Post a Comment